Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TIPARP | Q7Z3E1 | 6/20 | 0.45 |
| ▸ | CCRL2 | O00421 | 2/20 | 0.33 |
| ▸ | ACACB | O00763 | 2/20 | 0.33 |
| ▸ | FLT3 | P36888 | 3/20 | 0.32 |
| ▸ | KIT | P10721 | 1/20 | 0.32 |
| ▸ | HCRTR1 | O43613 | 3/20 | 0.32 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.31 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.31 |
| ▸ | FEN1 | P39748 | 1/20 | 0.31 |
| ▸ | TNF | P01375 | 1/20 | 0.31 |
| ▸ | CCR2 | P41597 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30550856 | 1.00 | TIPARP (0.45) | TIPARPCCRL2ACACBFLT3KIT | |
| SCHEMBL25321183 | 1.00 | TIPARP (0.45) | TIPARPCCRL2ACACBFLT3KIT | |
| SCHEMBL30550827 | 0.87 | TIPARP (0.49) | TIPARPCCRL2ALOX5APFEN1TNF | |
| SCHEMBL25321393 | 0.87 | TIPARP (0.46) | TIPARP | |
| SCHEMBL30550616 | 0.87 | TIPARP (0.46) | TIPARP | |
| SCHEMBL25321386 | 0.87 | TIPARP (0.46) | TIPARP | |
| SCHEMBL25319273 | 0.87 | TIPARP (0.49) | TIPARPCCRL2ALOX5APFEN1TNF | |
| SCHEMBL25319270 | 0.87 | TIPARP (0.49) | TIPARPCCRL2ALOX5APFEN1TNF | |
| SCHEMBL30550717 | 0.87 | TIPARP (0.46) | TIPARPTNF | |
| SCHEMBL26782305 | 0.87 | TIPARP (0.46) | TIPARPTNF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12459922-B2 | PARP7 inhibitors | GILEAD SCIENCES, INC. (US) | 2025-11-04 | — | — | US | disclosed |
| US-20230365529-A1 | PARP7 INHIBITORS | GILEAD SCIENCES, INC. | 2023-11-16 | — | — | US | disclosed |
| US-20230365529-A1 | PARP7 INHIBITORS | GILEAD SCIENCES, INC. | 2023-11-16 | — | — | US | disclosed |
| WO-2023147418-A1 | PARP7 INHIBITORS | GILEAD SCIENCES, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12459922-B2 | PARP7 inhibitors | PARP1, PARP11, PARP2 | TIPARP 491/4885CCRL2 3705/4885ACACB 3869/4885 |
| US-20230365529-A1 | PARP7 INHIBITORS | PARP1, PARP11, PARP2 | TIPARP 491/4885CCRL2 3705/4885ACACB 3869/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.